依达拉奉联合重组组织型纤溶酶原激活剂治疗急性脑梗死的效果分析

Effect analysis of edaravone combined with recombinant tissue-type plasminogen activator in the treatment of acute cerebral infarction

目的探讨依达拉奉联合重组组织性纤溶酶原激活剂治疗急性脑梗死的临床效果。方法选择于我院就诊发病6h内的急性脑梗死保守治疗70例,随机分为研究组(n=35)和对照组(n=35),研究组采用依达拉奉联合重组组织纤溶酶原激活剂治疗,对照组仅采用重组组织纤溶酶原激活剂治疗。比较2组治疗前后的神经功能缺损评分、脑缺血组织血管再通率、不良反应发生率。结果治疗前2组神经功能缺损评分差异无统计学意义(P>0.05),治疗后研究组神经功能缺损评分显著低于对照组(P<0.05),脑缺血组织血管再通率显著高于对照组(P<0.05),2组不良反应发生率差异无统计学意义(P>0.05)。结论依达拉奉联合重组组织型纤溶酶原激活剂治疗急性脑梗死患者效果显著,能显著改善患者的神经缺损症状,促进血管再通,值得推广应用。

Objective To investigate the clinical effects of edaravone combined with recombinant tissue-type plasminogen activator（rt-PA）in the treatment of acute cerebral infarction（ACI）.Methods Seventy ACI patients within six hours of onset receiving conventional treatment in our hospital were randomly divided into the study group（n=35）and the control group（n=35）.Patients in the study group were treated with edaravone combined with rt-PA,and patients in the control group were only treated with rt-PA.The scores of neurological deficits before and after treatment,the recanalization rate of cerebral ischemia and the incidence of adverse reactions were compared.Results There was no significant difference in scores of neurological deficits between the two groups before treatment（P 〉0.05）,and the scores in the study group were significantly lower than those in the control group（P 〈0.05）.The study group showed higher recanalization rate of cerebral ischemia compared with the control group（P 〈0.05）.No significant difference was found in the incidence of adverse reactions between the two groups（P 〈0.05）.ConclusionEdaravone combined with rt-PA can be effective in the treatment of acute cerebral infarction.It can significantly improve the symptoms of nerve defects and promote the recanalization of cerebral ischemia.